NAGE - NASDAQ

Niagen Bioscience Inc

NAGE·NASDAQ

$3.50

-1.1%

HealthcareBiotechnology

Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$278.76M

EPS0.2200

P/E Ratio15.91

Earnings Date08/05/2026

nage

Net Debt Issuance

Last Annual Value

-12.00K

3-Year CAGR

5-Year CAGR

46%

10-Year CAGR

Adjust for Inflation

Niagen Bioscience Inc Competitors Analysis of Net Debt Issuance

NAGE · NASDAQ

Company	Net Debt Issuance	CAGR 3Y	CAGR 5Y	CAGR 10Y
Niagen Bioscience Inc NASDAQ:NAGE	-12.00K	N/A	N/A	N/A
Prothena Corporation plc NASDAQ:PRTA	0.00	N/A	N/A	N/A
Akebia Therapeutics, Inc. NASDAQ:AKBA	4.63M	N/A	-36.5%	N/A
Ventyx Biosciences, Inc. NASDAQ:VTYX	0.00	N/A	N/A	N/A
Keros Therapeutics, Inc. NASDAQ:KROS	0.00	N/A	N/A	N/A
REGENXBIO Inc. NASDAQ:RGNX	0.00	N/A	N/A	N/A
Olema Pharmaceuticals, Inc. NASDAQ:OLMA	3.00M	N/A	N/A	N/A
Corvus Pharmaceuticals, Inc. NASDAQ:CRVS	0.00	N/A	N/A	N/A
KalVista Pharmaceuticals, Inc. NASDAQ:KALV	160.72M	N/A	N/A	N/A
Rigel Pharmaceuticals, Inc. NASDAQ:RIGL	-7.50M	N/A	N/A	N/A
Zevra Therapeutics, Inc. NASDAQ:ZVRA	0.00	N/A	N/A	N/A

Niagen Bioscience Inc Fair Value Envelope

NAGE · NASDAQ

Our analysis suggests that NAGE has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.5, this represents a potential HIDDEN relative to our calculated worth for Niagen Bioscience Inc.

HIDDEN

Intrinsic Value

Current Price: $3.5

Related Guides

Blog Categories

Continue your NAGE research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.